This company has been marked as potentially delisted and may not be actively trading. Vermillion (VRML) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock VRML vs. CDIO, TRIB, BMRA, VRAX, AWH, TNFA, MYMD, NAVB, IDXX, and LNTHShould you be buying Vermillion stock or one of its competitors? The main competitors of Vermillion include Cardio Diagnostics (CDIO), Trinity Biotech (TRIB), Biomerica (BMRA), Virax Biolabs Group (VRAX), Aspira Women's Health (AWH), TNF Pharmaceuticals (TNFA), MyMD Pharmaceuticals (MYMD), Navidea Biopharmaceuticals (NAVB), IDEXX Laboratories (IDXX), and Lantheus (LNTH). These companies are all part of the "medical" sector. Vermillion vs. Cardio Diagnostics Trinity Biotech Biomerica Virax Biolabs Group Aspira Women's Health TNF Pharmaceuticals MyMD Pharmaceuticals Navidea Biopharmaceuticals IDEXX Laboratories Lantheus Vermillion (NASDAQ:VRML) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, community ranking, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations. Which has stronger earnings & valuation, VRML or CDIO? Cardio Diagnostics has lower revenue, but higher earnings than Vermillion. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVermillion$4.54M0.58-$15.24MN/AN/ACardio Diagnostics$34.89K582.73-$8.38MN/AN/A Does the media refer more to VRML or CDIO? In the previous week, Cardio Diagnostics had 1 more articles in the media than Vermillion. MarketBeat recorded 1 mentions for Cardio Diagnostics and 0 mentions for Vermillion. Vermillion's average media sentiment score of 0.00 beat Cardio Diagnostics' score of -1.00 indicating that Vermillion is being referred to more favorably in the media. Company Overall Sentiment Vermillion Neutral Cardio Diagnostics Negative Is VRML or CDIO more profitable? Vermillion has a net margin of -307.31% compared to Cardio Diagnostics' net margin of -22,732.03%. Vermillion's return on equity of -155.25% beat Cardio Diagnostics' return on equity.Company Net Margins Return on Equity Return on Assets Vermillion-307.31% -155.25% -103.47% Cardio Diagnostics -22,732.03%-258.85%-191.20% Do analysts rate VRML or CDIO? Cardio Diagnostics has a consensus price target of $2.00, indicating a potential upside of 412.95%. Given Cardio Diagnostics' stronger consensus rating and higher probable upside, analysts plainly believe Cardio Diagnostics is more favorable than Vermillion.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vermillion 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cardio Diagnostics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer VRML or CDIO? Vermillion received 200 more outperform votes than Cardio Diagnostics when rated by MarketBeat users. However, 80.00% of users gave Cardio Diagnostics an outperform vote while only 66.67% of users gave Vermillion an outperform vote. CompanyUnderperformOutperformVermillionOutperform Votes20466.67% Underperform Votes10233.33% Cardio DiagnosticsOutperform Votes480.00% Underperform Votes120.00% Do institutionals and insiders believe in VRML or CDIO? 18.1% of Vermillion shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 4.4% of Vermillion shares are owned by insiders. Comparatively, 22.3% of Cardio Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk & volatility, VRML or CDIO? Vermillion has a beta of 3.47, suggesting that its stock price is 247% more volatile than the S&P 500. Comparatively, Cardio Diagnostics has a beta of 3.73, suggesting that its stock price is 273% more volatile than the S&P 500. SummaryCardio Diagnostics beats Vermillion on 9 of the 16 factors compared between the two stocks. Get Vermillion News Delivered to You Automatically Sign up to receive the latest news and ratings for VRML and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRML vs. The Competition Export to ExcelMetricVermillionDiagnostic Substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.63M$2.30B$5.31B$7.35BDividend YieldN/A0.79%5.45%4.29%P/E Ratio-0.166.9321.9417.81Price / Sales0.5846.40380.9597.70Price / CashN/A15.7538.2634.64Price / Book0.302.936.453.98Net Income-$15.24M-$65.73M$3.22B$247.81M Vermillion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRMLVermillionN/A$0.03-67.1%N/A-99.2%$2.63M$4.54M-0.1643Gap DownHigh Trading VolumeCDIOCardio Diagnostics1.7992 of 5 stars$0.39-4.1%$2.00+414.8%-64.2%$20.26M$34,890.000.001Short Interest ↑Negative NewsTRIBTrinity Biotech0.9097 of 5 stars$0.580.0%N/A-69.4%$10.47M$59.13M-0.26480Analyst ForecastBMRABiomerica0.2248 of 5 stars$0.55+3.4%N/A-36.8%$10.14M$5.58M-1.6360Earnings ReportStock SplitShort Interest ↑News CoverageGap UpVRAXVirax Biolabs Group2.6847 of 5 stars$1.02-8.1%$3.00+194.1%+46.2%$3.30M$84,872.000.005Gap DownAWHAspira Women's Health2.1999 of 5 stars$0.10+0.9%$5.50+5,512.2%-97.7%$2.92M$9.18M-0.08110Short Interest ↓News CoverageGap UpTNFATNF PharmaceuticalsN/A$0.27-2.0%N/AN/A$745,000.00N/A0.006Earnings ReportNews CoveragePositive NewsGap UpMYMDMyMD PharmaceuticalsN/A$0.28+7.1%N/A-92.7%$654,000.00N/A0.006Gap DownHigh Trading VolumeNAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-98.3%$60,000.00$8,126.000.0010Analyst ForecastNews CoverageIDXXIDEXX Laboratories4.7932 of 5 stars$404.65+3.5%$523.75+29.4%-13.8%$32.79B$3.90B37.9210,800Positive NewsLNTHLantheus4.3477 of 5 stars$102.13+0.1%$129.43+26.7%+62.6%$6.99B$1.53B16.99700News CoveragePositive News Related Companies and Tools Related Companies Cardio Diagnostics Competitors Trinity Biotech Competitors Biomerica Competitors Virax Biolabs Group Competitors Aspira Women's Health Competitors TNF Pharmaceuticals Competitors MyMD Pharmaceuticals Competitors Navidea Biopharmaceuticals Competitors IDEXX Laboratories Competitors Lantheus Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRML) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vermillion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vermillion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VRML Stock Free VRML Stock Alerts